Yarrow Bioscience posts Q3 net loss

Overview

• Biotechnology firm's Q3 net loss totaled $9.7 mln

• Company completed $172.5 mln public offering, boosting cash to $268.9 mln

• Merger with VYNE Therapeutics completed in July 2026

Outlook

• Yarrow expects topline results from Phase 2a GD trial in second half of 2027

• Company anticipates Phase 2b GD trial enrollment to begin in first half of 2028

• Yarrow expects cash and equivalents to fund operations into 2030

Result Drivers

• CLINICAL TRIAL PROGRESS - Co said Q3 results reflect ongoing enrollment and dosing in Phase 2a/2b trial for YB-101 in Graves’ disease

• CAPITAL RAISE - Q3 results include impact of $172.5 mln public offering completed in September, boosting cash position

• OPERATING EXPENSES - Net loss driven by R&D and G&A expenses as company invests in clinical development and operations

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Yarrow Bioscience, Inc. is $58.00, about 221.3% above its November 11 closing price of $18.05

Reuters Recommended Reads

• Nov 10 - Ovid Therapeutics Q3 net loss widens as R&D spending rises

• Nov 9 - Structure Therapeutics Q3 loss widens on higher R&D costs

• Nov 10 - Capricor Therapeutics Q3 net loss widens as expenses rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)